Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

Abstract

These results envisage that CAB may represent a worthy therapeutic tool in acromegalic patients, inducing a degree of IGF-I and GH suppression comparable to SAs, administered by the oral route and much less expensive.